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The purpose of the present study was to assess the degree of protection of inhaled sahneterol against 
exercise-induced bronchoconstriction (EIB) after chronic compared with single dosing in patients with 
asthma. Twelve patients with exercise-induced asthma took part in a randomized double-blind crossover study 
to compare the duration of action of inhaled salmeterol 50,~g twice daily for 4 weeks with that of placebo. A 
standardized exercise test was performed at 6 h and 12 h after dosing on the first and last day of each 
treatment period. Salmeterol produced significant protection against EIB at 6 and 12 h after the first dose in 
comparison with placebo, whereas there was no significant attenuation of EIB after 4 weeks of chronic 
treatment with salmeterol. The percentage fall in FEV, after exercise challenge at 6 h was (first dose): placebo 
34.8 & 4.9% vs. sahneterol 11.9 * 2.8% (PcO.05); (4 weeks): placebo 32.9 f 5.3% vs. sahneterol 24.0 f 4.4% 
(NS). These results suggest that tachyphylaxis may develop to the functional antagonism of salmeterol against 
EIB. 
Introduction 
Exercise induced bronchoconstriction (EIB) is a 
common and not infrequent limiting feature in 
many patients with asthma. Several therapeutic 
agents offer a degree of protection for patients and 
&adrenoceptor agonists are the most effective and 
most widely used (1). The short duration of action of 
drugs such as salbutamol may result in symptoms 
occurring during more prolonged periods of exercise. 
However, recent availability of long-acting & 
adrenoceptor agonists has given hope of more 
prolonged protection against EIB. 
Salmeterol is one such long-acting &agonist 
which has been shown to protect against EIB in 
single dosing studies (2,3), in that a single dose of 
salmeterol 50 lug produces significant protection 
against EIB for up to 12 h. However, it remains 
unclear whether tolerance might develop to the 
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protective effects of salmeterol against EIB after 
repeated doses. The aim of the present study was 
to compare the duration of protection conferred 
against EIB by inhaled salmeterol with that of 
placebo, after single dosing and after 4 weeks of 
continuous treatment. 
Methods 
PATIENTS 
Patients were eligible to take part in this study if 
they were between 18 and 50 years old and had 
previous evidence of reversible airways obstruction 
with exercise. All subjects were required to have a 
resting FEV, of at least 65% of predicted normal (4) 
and a decrease in FEV, of at least 20% following 
standard exercise challenge. No patient who had a 
significant exacerbation of asthma requiring a change 
of medication within the month prior to the study 
was included. Any subject with other clinically sig- 
nificant disease or contraindication to exercise testing 
was excluded. All patients gave written informed 
consent and the study was approved by the Tayside 
Medical Ethics Committee. 
Details of patient characteristics are shown in 
Table 1. The study group consisted of 12 asthmatic 
patients (eight male, four female), aged between 
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Table I Patient characteristics 
Patient Sex 
Age 
W 
Allergen 
skin test FEVl 
FEV, 
%pred. Medication 
1 M 32 
2 M 22 
3 F 24 
4 F 27 
5 M 23 
6 M 36 
I M 23 
8 M 24 
9 F 22 
10 M 33 
11 F 23 
12 M 21 
+ve 
NA 
+ve 
NA 
+ve 
NA 
-ve 
+ve 
+ve 
+ve 
+ve 
NA 
4.40 104 S p.r.n. 
465 101 Nil 
3.80 123 S p.r.n. 
3.30 93 Nil 
4.50 108 S(SO0) B(200) 
3.20 89 S(400) B(200)T 
4.90 107 Nil 
4.85 II Nil 
2.75 85 S p.r.n. 
4.85 115 S C p.r.n. 
4.95 155 S B(400) p.r.n. 
4.80 114 S(800) 
S: Salbutamol inhaled (total daily dose in pg or p.r.n.). B: Beclomethasone inhaled (total daily 
dose inpg). T: Theophylline SR 400 mg nocte. C: Cromoglycate inhaled 10 mg qds. NA: Result 
of skin-prick test not available. [Predicted values are from Cotes (4)]. 
19-36 (mean 25.8 years). Median duration of asthma 
was 13.5 years (range 3-23 years). All subjects were 
non-smokers. At the initial pre-treatment visit mean 
FEV, was 4.45 1 (range 2.7554.95) and FVC was 
4.82 1 (range 3.0-5.9). Mean maximum FEV, as a 
percentage of predicted was 105.7% (range 76.5- 
154.7). 
During the study period inhaled corticosteroid 
treatment was continued providing the dose re- 
mained unchanged. Cromoglycate was also contin- 
ued at a stable dose, but was withheld for 24 h before 
all study days. Methylxanthines were treated simi- 
larly. At all times throughout the 4-week study 
period, free use of a salbutamol inhaler was permitted 
as required, except for a period of 8 h prior to each 
exercise test. On study days, the short-acting 
&agonist rimiterol (2OOpg) was used for relief if 
required after exercise challenge. Rimiterol was 
chosen because it has a much shorter duration of 
effect than salbutamol. Patients were allowed to 
continue with subsequent challenges provided that 
pre-exercise FEV, had returned to normal, and that 
rimiterol had not been used for at least 5 h 
previously. 
PROTOCOL 
Study medication consisted of a metered dose 
inhaler delivering either placebo or salmeterol 50,~g 
per puff. One puff was taken morning and night on 
each day of each treatment period. The design of the 
trial was a randomized, double-blind, crossover 
study. After an initial visit to assess the eligibility of 
the patient for inclusion into the study, there were 
two treatment periods of 4 weeks with a washout 
period of 1 week in between. The treatment random- 
ization blocks were balanced. A standardized exercise 
test was performed at 6 and 12 h post dosing on the 
first and last day of each treatment period. 
EXERCISE CHALLENGE 
The standard exercise test used was a modification 
of the method of Eggleston et al. (5). Subjects were 
exercised on a treadmill for 6 min. Speed and gradi- 
ent were increased in a step-wise fashion until an 
exercise level sufficient to increase heart rate to 85% 
of predicted value for that subject was achieved. 
These levels were noted and were used in subsequent 
exercise tests, but were adjusted if required to repro- 
duce the previous heart rate response. Subjects 
breathed through a two-way valve inspiring dry air 
from a Douglas bag and exhaling into a mixing 
chamber. Ventilation, respiratory rate and expired 
oxygen and carbon dioxide concentration were 
measured and from these data oxygen uptake was 
calculated during each exercise test. 
At the initial study visit a standard exercise test 
was then performed and FEV, was measured for up 
to 30 min after exercise, to confirm a drop in FEV, 
from the pre-exercise value of at least 20% and 
establish that patients exhibited a significant bron- 
choconstrictor response to exercise. On visits 2, 3, 4 
and 5, on the first and last day of each study period, 
the subject attended the laboratory 6 h after taking 
one puff of study medication at home. If the two 
highest FEVi values were not within 5% of each 
other, or were below 65% of predicted normal, the 
subject was asked to return the next day. A standard 
exercise test was then performed, with follow-up 
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spirometry over 1 h (at 5, 10,20, 30,60 min). Subjects 
returned to the laboratory later that day, 12-h post- 
dosing and, after baseline spirometry, performed a 
further standard exercise test followed by FEV, 
measurement over 1 h as before. Spirometry was 
performed in triplicate according to American 
Thoracic Society Criteria (6), using a dry bellows 
spirometer (Vitalograph, Bucks, U.K.). 
DATA ANALYSIS 
The efficacy of each treatment was assessed by 
comparing the maximum fall in FEV, (as a percent- 
age of the pre-exercise FEV, value) during the 30 min 
after exercise. The primary end point for the analysis 
was the comparison between salmeterol and placebo, 
6 and 12 h after single (first dose) and chronic (4 
weeks) dosing. A secondary end point was to com- 
pare within treatments (i.e. for placebo or salmeterol) 
in order to compare values between single and 
chronic dosing (i.e. first dose vs. 4 weeks). The data 
was analysed using a non-parametric crossover 
analysis, accounting for any carry-over effect (7). All 
statistical tests were carried out with a two-sided 
alternative hypothesis and were considered statisti- 
cally significant at the 5% level (i.e. PcO.05). Ax2 test 
was used to compare numbers of patients who had 
less than 10% fall in FEV, after exercise, both at 6 
and 12 h after inhaling salmeterol. 
Results 
PRE+EXERCISE FEVl 
Mean baseline values for FEV, were significantly 
(PcO.05) higher after salmeterol compared with pla- 
cebo at 6 and 12 h after both the first dose and after 
4 weeks of treatment [Fig. l(a), Table 21. There were 
no significant differences between the first and last 
dose values at 6 and 12 h for either placebo or 
salmeterol. 
POST-EXERCISE FEV1 
In comparison with placebo, salmeterol produced 
significant (PcO.05) protection against EIB after the 
first dose at both 6 and 12 h [Fig. l(b), Table 31. 
However, after 4 weeks of treatment, there was no 
significant difference between placebo and salmeterol 
at either 6 or 12 h. 
There were no significant differences between first 
and last dose (4 weeks) values for placebo at 6 or 
12 h. Salmeterol produced significantly (P<O.O5) 
less protection against EIB at 6 h, after 4 weeks 
compared with the first dose. Whilst there was a 
trend towards reduced protection after 4 weeks of 
4.6 I 
4.20 
t 
3.00 
Day1 41 1 
6h 
Day 1 4 Weeks 
12h 
Day 1 4 Weeks Day 1 4 Weeks 
6h 12 h 
Fig. I(a) Pre-exercise values for FEV, at 6 and 12 h after 
the first dose (day 1) and 4 weeks of continuous therapy 
with inhaled salmeterol 5Opg bd or placebo. Values are 
shown as mean and SEM. *Denotes a significant difference 
(PcO.05) between salmeterol (a) and placebo (0). 
(b) Percentage fall in FEV, after exercise challenge [as in 
Fig. l(a)]. Sahneterol (n), placebo (0). 
Table 2 Pre-exercise FEV, after first dose and 4 weeks 
Placebo Salmeterol P 
First dose -6h 3.81 * 0.26 4.20 f 0.25 CO.05 
-12h 3.65 i 0.25 4.15 f 0.24 CO.05 
4 weeks -6h 4.00 It 0.22 4.20 z!z 0.22 co.05 
- 12h 3.86 zk 0.25 4.16 f 0.23 co.05 
Values of FEV, (1) are shown as means It SEM. P refers to 
comparison between sahneterol and placebo at 6 and 12 h 
after the first and last dose, following treatment for 4 weeks, 
salmeterol in comparison with the first dose at 12 h, it 
was not of significance. 
After the first dose of salmeterol, the frequency of 
patients who had less than 10% fall in FEV, after 
exercise was n=8 at 6 h, and n=4 at 12 h. After 4 
weeks of salmeterol, corresponding values were n=l 
at 6 h (PcO.05 vs. first dose), and n=3 at 12 h. No 
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Table 3 Percentage fall in FEV, following exercise chal- 
lenge after first dose and 4 weeks 
Placebo Salmeterol P 
First dose -6h 34.8+4.9 11.9 * 2.8 co.05 
- 12 h 24.5 + 3.6 14.6 f 2.4 co.05 
4 weeks -6h 32,9f5.3 24.0 f4.4* NS 
~ 12 h 28.2 + 5.3 23.4* 5.8 NS 
Values are shown as means f SEM. P refers to comparison 
between placebo and salmeterol at 6 and 12 h after the first 
dose and after last dose, following treatment for 4 weeks. 
*Significant (PcO.05) difference between values for salme- 
terol after the first dose and 4 weeks. 
tection against histamine challenge, whilst the 
bronchodilator response remained intact. Similar 
effects have been reported after 7 days of inhaled 
terbutaline in terms of reduced protection against 
methacholine and AMP, with an unchanged 
bronchodilator effect (13). Cheung et al. (14) in a 
parallel group study compared the effects of inhaled 
salmeterol50 pug bd and placebo given for a period of 
8 weeks to patients with mild asthma. They found 
that regular treatment with salmeterol lead to toler- 
ance to its protective effect against methacholine 
despite well maintained bronchodilatation. Two 
other studies have also shown a dissociation between 
the broncodilator properties of salbutamol and its 
efficacy in preventing EIB (15,16). 
patient required rescue medication with rimiterol 
after exercise challenge on days when salmeterol was 
given, whereas five patients needed to use rimiterol 
rescue after exercise when placebo had been given. In 
all cases, there was a period of at least 5 h prior to the 
next exercise test at 12 h, and pre-exercise FEV, had 
returned to at least baseline values. 
Discussion 
The results of the present study showed that 
inhaled salmeterol produced significant protection 
against EIB compared with placebo at 6 and 12 h 
after the first dose, whereas there was no significant 
difference from placebo after 4 weeks of continuous 
dosing. This suggests that tachyphylaxis developed to 
the functional antagonism of salmeterol against the 
stimulus of EIB. 
The above results would therefore suggest that 
tolerance to the protection against bronchoconstric- 
tion stimuli is a class effect of inhaled &-agonists, 
rather than a specific property of long-acting drugs. 
At present it is not possible to explain the apparent 
dissociated tolerance between bronchodilator effects 
and functional antagonism, although it is interesting 
to speculate on possible mechanisms. Tachyphylaxis 
to &agonists may occur either as a consequence of 
receptor uncoupling or receptor down-regulation 
(17). However, it has been shown both in vitro (18) 
and in vivo (8) that systemic /&-receptors more readily 
undergo down-regulation than lung &receptors. 
Indeed it is also possible that there may be differences 
in the propensity for tachyphylaxis between ,$- 
receptors on bronchial smooth muscle and mast cells 
(13). 
The question of tolerance to the effects of j&- 
agonists has been debated for many years, although 
interest has been highlighted with the advent of 
the long-acting agents such as sahneterol and for- 
moterol. In considering the phenomenon of tachy- 
phylaxis it is important to distinguish between 
effects on basal bronchomotor tone and functional 
antagonism of bronchoconstrictor stimuli. To date, 
studies with either short or long-acting inhaled 
&agonists have suggested that tolerance does not 
occur to peak bronchodilator response after con- 
tinuous treatment (8-10). It has however been 
found that tachyphylaxis may occur to the duration 
but not peak bronchodilator response with inhaled 
salbutamol (11). 
There are some methodological problems which 
make it difficult to evaluate the effect of chronic 
therapy on EIB. There is an inherent degree of 
variability in the bronchoconstrictor response to 
exercise (19). Hence, any drug effect must be large in 
order to show a significant difference from placebo. 
In the present study, although there was a diminished 
effect with sahneterol at 6 h when comparing 
responses after the first dose and 4 weeks, there was 
no significant difference between placebo values at 
the corresponding time points. It is likely that the 
absence of a significant difference between first and 
last dose effects of salmeterol after 12 h was due to 
type II error consequent upon the small sample size, 
since there was a clear trend towards an attenuated 
effect after chronic dosing. 
There is now increasing evidence to suggest that Patient selection may also have influenced our 
tachyphylaxis occurs to the protective effects of results in that the patients had mild asthma and were 
inhaled &,-agonists against a number of different taking minimal therapy. Thus, it is therefore not 
bronchoconstrictor stimuli. Vathenen et aZ. (12) possible to extrapolate our results to patients with 
found that treatment for 2 weeks with inhaled more severe asthma, and to patients taking inhaled 
terbutaline resulted in an attenuation of its pro- corticosteroids. It is known that corticosteroids may 
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up-regulate &receptors (20,21) and hence might 
conceivably prevent tachyphylaxis from occurring. 
Henricksen and Dahl (22) showed that treatment 
with inhaled budesonide and terbutaline for 4 weeks 
significantly reduced EIB and that the effects of 
budesonide and terbutaline were additive. It would 
therefore be interesting to evaluate the effects of 
regular inhaled salmeterol given in conjunction with 
inhaled corticosteroid in order to assess whether 
inhaled corticosteroids might protect against tachy- 
phylaxis developing to EIB and other bronchocon- 
strictor stimuli. This would be particularly relevant in 
that inhaled long-acting &agonists are usually pre- 
scribed to patients who are already receiving inhaled 
corticosteroids. 
In the present study, salmeterol also produced 
significant increases in pre-exercise FEV, compared 
with placebo. This might have resulted in an under- 
estimation of the percentage fall in FEV, after exer- 
cise, in that a larger starting value will result in a 
proportionately smaller percentage fall from baseline 
(23). More importantly, there was no difference in 
pre-exercise FEV, values for salmeterol between first 
and last dose, and hence this would not explain the 
reduced protection against EIB afforded by salme- 
terol after chronic dosing. The washout period of 1 
week between placebo and salmeterol was considered 
to be sufficiently long to allow the airway effects of 
salmeterol to wear off prior to the first dose of 
placebo. Furthermore there was no evidence of any 
carryover effect between measurements from the 
statistical analysis. 
In summary, we have demonstrated that the 
protection afforded by inhaled sahneterol is dimin- 
ished after twice daily dosing for 4 weeks in compari- 
son with placebo. Further studies are indicated to 
evaluate whether this same phenomenon occurs in 
patients who are also receiving treatment with 
inhaled corticosteroids. 
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